The in vitro spectrum of a novel des-fluoro(6) quinolone, BMS-284756, was compared with those of five fluoroquinolones (trovafloxacin, moxifloxacin, levofloxacin, ofloxacin, and ciprofloxacin). BMS-284756 was among the most active and often was the most active quinolone against staphylococci (including methicillin-resistant strains), streptococci, pneumococci (including ciprofloxacin-nonsusceptible and penicillin-resistant strains), and Enterococcus faecalis. BMS-284756 inhibited Ϸ60 to Ϸ70% of the Enterococcus faecium (including vancomycin-resistant) strains and 90 to 100% of the Enterobacteriaceae strains and gastroenteric bacillary pathogens at the anticipated MIC susceptible breakpoint (<4 g/ml). Against the nonfermenters, BMS-284756 inhibited 90 to 100% of Pseudomonas fluorescens, Pseudomonas stutzeri, Stenotrophomonas maltophilia, Flavobacterium spp., and Acinetobacter spp. and 72% of Pseudomonas aeruginosa strains at 4 g/ml. Against anaerobic bacteria, BMS-284756 was among the most active, inhibiting essentially all strains tested. It had very low MICs against the fastidious and atypical microbial species, in particular against mycoplasmas or ureaplasmas, Borrelia burgdorferi, chlamydia, and gonococci. These results indicate that with its broad antibacterial spectrum, BMS-284756 should be evaluated clinically for the treatment of community and nosocomial infections.
RESULTS AND DISCUSSION
All of the results discussed in this section are listed in Table 1 .
Gram-positive aerobic bacteria. BMS-284756 was the most active quinolone against MS and MR staphylococci. BMS-284756 was generally 2-fold more active than TVA and MFX and 8-to 32-fold more active than LVX, OFX, and CIP. The quinolones inhibited MS staphylococci uniformly, with MICs at which 50% of the isolated were inhibited (MIC 50 s) and MIC 90 s generally being equal. By comparison, the quinolone MIC ranges were broader for MR staphylococci, with MIC 50 s and MIC 90 s differing by 32-to 64-fold. The fact that quinolone resistance is more commonly encountered among MR than MS staphylococcal clinical isolates accounts for the higher quinolone MIC 90 s for MR strains (3, 7) . In fact, for 40 to 50% of MR strains tested, CIP MICs were Ն2 g/ml, compared with 0% of MS strains. For all the MR S. aureus strains, BMS-284756 MICs were Յ2 g/ml.
The quinolones can be grouped by their streptococcal and pneumococcal potencies. BMS-284756, TVA, and MFX were about 10-fold more active than LVX, OFX, and CIP against these organisms. Along with BMS-284756 (MIC 90 s ϭ 0.12 to 0.25 g/ml), LVX, TVA, and MFX covered all the streptococci and pneumococci at their susceptible breakpoints, but only BMS-284756 covered all Streptococcus pneumoniae strains with CIP MICs of Ն2 g/ml (85% of which had OFX MICs of Ն4 g/ml), and for 90% of the latter isolates BMS-284756 MICs were Յ0.5 g/ml. As with streptococci, the enterococci were more susceptible to BMS-284756, TVA, and MFX than to LVX, OFX, and CIP. The quinolones were more active against Enterococcus faecalis than to Enterococcus faecium, the latter being more frequently resistant to quinolones. While BMS-284756, TVA, MFX, and LVX covered Ϸ90% or more of the E. faecalis and VanC enterococcal species (i.e., Enterococcus gallinarum and Enterococcus casseliflavus), only BMS-284756 covered Ͼ50% of E. faecium and VanA and VanB strains (comprised primarily of E. faecium) at Յ4 g/ml.
Gram-negative aerobic bacteria. The quinolones have good activities against Enterobacteriaceae. Overall, CIP was the most active against Enterobacteriaceae, except Providencia spp. BMS-284756 was less active against the Enterobacteriaceae, but for almost all of the Enterobacteriaceae strains, BMS-284756 MICs were Յ4 g/ml, levels that are achievable in plasma for this quinolone.
For bacterial species associated with gastroenteritis (Salmonella spp., Shigella spp., Yersinia enterocolitica, Aeromonas hydrophila, Vibrio cholerae, and Campylobacter jejuni), all the quinolones showed potent and generally similar activities.
Nonfermentative bacteria. Pseudomonal susceptibility to the quinolones is species dependent. Against Pseudomonas aeruginosa, CIP remained the most active. Approximately 90% of the P. aeruginosa strains were susceptible to CIP, TVA, and LVX, 72% were susceptible to OFX and BMS-284756 (at Յ4 g/ml), and 28% were susceptible to MFX. All Pseudomonas stutzeri strains were susceptible to the six quinolones tested. All of the Pseudomonas fluorescens strains were susceptible to LVX, compared to the 87 to 93% of strains that were susceptible to CIP, TVA MFX, and BMS-284756 (at Յ4 g/ml) and 67% that were susceptible to OFX.
In contrast, CIP was among the least active quinolones against the pseudomonas-related species, being inactive against Burkholderia cepacia, Stenotrophomonas maltophilia, and other nonfermenters (Flavobacterium and Acinetobacter spp.). While BMS-284756 MIC 90 s for Stenotrophomonas maltophilia, Flavobacterium spp., and Acinetobacter spp. were Յ4 g/ml, Burkholderia cepacia and Alcaligenes spp. were generally resistant.
Anaerobic bacteria. The broadest antianaerobic bacterial spectra were observed with BMS-284756, TVA, and MFX. BMS-284756 was very active against anaerobic bacteria, inhibiting all but one peptostreptococcal strain at 4 g/ml. 
